Apr 26, 2017
It’s April, which in Japan means baseball is back, and cherry blossoms are in full bloom (side note: April really is the best time to visit Japan for those considering a trip). April is also the start of the 2nd quarter, and at Locust Walk Japan we have noticed a...
Apr 17, 2017
Our Q1 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: Biopharma public indices Biopharma IPOs Deal activity for strategic partnership...
Apr 17, 2017
Boston, MA, San Francisco, CA, Tokyo, Japan and Cologne, Germany April 17th, 2017—Locust Walk, a leading life sciences transaction advisory firm, is pleased to announce that it has appointed Hunt Henrie as a Managing Director. Based in the firm’s Boston, MA office,...
Apr 12, 2017
Once the strategic analysis is complete, the target identified and the exclusivity period is in effect, things start to get interesting in a buy-side transaction. The due diligence process provides the acquirer the opportunity to further assess strategic fit,...
Apr 5, 2017
While border control is one of today’s biggest hot-button political topics, US biotech companies are clearly not building any walls when it comes to deal-making. In fact, Locust Walk views regional deal-making outside of the US as a significant value driver for US...
